Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CHEMOCENTRYX, INC.

(A0NBM2)
Verzögert Nasdaq  -  22:00:00 19.10.2022
51.99 USD   +0.06%
2022HBM Healthcare rutscht im H1 2022/23 mit 34 Millionen Franken in Verlustzone
AW
2022Amgen schließt die Übernahme von ChemoCentryx ab
MT
2022Chemocentryx, Inc. kündigt Änderungen in der Geschäftsführung an
CI
ÜbersichtKurseChartsNewsRatingsUnternehmenFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über CHEMOCENTRYX, INC.
2022ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Global BM..
2022ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P TMI Index
2022ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from S&P Biotechno..
2022HBM Healthcare confirme une perte semestrielle de 34,2 millions
2022Amgen Completes ChemoCentryx Acquisition
2022Chemocentryx, Inc. : Termination of a Material Definitive Agreement, Completion of Acquisi..
2022Chemocentryx, Inc. Announces Executive Changes
2022Amgen successfully completes acquisition of chemocentryx
2022ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Compos..
2022Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentry..
2022ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from NASDAQ Biotec..
2022Chemocentryx, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K)
2022ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and Ame..
2022ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and Ame..
2022ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, ..
2022HBM Healthcare prévoit une perte de 34 millions au 1er semestre 2022/23
2022Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease
2022Chemocentryx, Inc. : Other Events (form 8-K)
2022ChemoCentryx Announces TAVNEOS (avacopan) Presentations at Upcoming Medical Conferences
2022ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conference..
2022Insider Sell: Chemocentryx
2022UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease
2022Biotech stocks pin bounce back hopes on M&A boost
2022Insider Sell: ChemoCentryx
2022ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
2022ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
2022Insider Sell: ChemoCentryx
2022CHEMOCENTRYX, INC. Management's Discussion and Analysis of Financial Condition and Res..
2022ChemoCentryx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended..
2022Amgen Signals Additional $100 Million Hit to Revenue From Foreign Exchange Following Vo..
2022MarketScreener’s World Press Review : August 5, 2022
2022Coinbase & BlackRock unis, Amgen prend Chemocentryx..
2022Healthcare Shares Slip Amid Deal News -- Healthcare Roundup
2022Amgen 2Q Profit Jumped After Write-Off From 2021 Acquisition
2022Sector Update: Health Care Stocks Slipping Ahead of Thursday Close
2022Sector Update: Health Care
2022Amgen to Acquire Drugmaker ChemoCentryx in $3.7 Billion Deal
2022Top Midday Gainers
2022Amgen : accord pour fera l'acquisition de ChemoCentryx
2022ChemoCentryx Shares Soar Premarket on Amgen Takeover Deal
2022Amgen to Acquire ChemoCentryx in $3.7 Billion Deal
2022Chemocentryx, Inc. : Entry into a Material Definitive Agreement, Regulation FD Disclosure,..
2022Amgen to buy ChemoCentryx for $3.7 billion
2022Amgen to acquire chemocentryx for $4 billion in cash
2022Amgen Inc. (NasdaqGS:AMGN) entered into a definitive agreement to a..
2022ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, ..
2022ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, ..
2022Chemocentryx : Announces Appointment of Jennifer L. Herron to Board as Independent Directo..
2022Chemocentryx, Inc. : Change in Directors or Principal Officers, Regulation FD Disclosure, ..
2022ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Direct..
2022Chemocentryx, Inc. Announces Appointment of Jennifer L. Herron to Board as Independent ..
2022Chemocentryx, Inc. : Change in Directors or Principal Officers (form 8-K)
2022ChemoCentryx, Inc. Appoints Yi Ching Yau as Senior Vice President, Finance and Principa..
2022ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Admi..
2022ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Admi..
2022Chemocentryx Inc. Reports Safety Results Available from Ongoing Phase I Trial of Orally..
2022Chemocentryx : Announces Changes to its Board of Directors - Form 8-K
2022Chemocentryx, Inc. : Change in Directors or Principal Officers, Submission of Matters to a..
2022ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferen..
2022ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology Conferen..
2022ChemoCentryx Announces Changes to its Board of Directors
2022ChemoCentryx Announces Changes to its Board of Directors
2022ChemoCentryx Announces Changes to its Board of Directors
2022ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meetin..
2022ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meetin..
2022ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
2022ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
2022ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and..
2022ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and..
2022CHEMOCENTRYX, INC. Management's Discussion and Analysis of Financial Condition and Res..
2022ChemoCentryx Q1 Loss Widens as Revenue Declines
2022Chemocentryx : Q1 Earnings Snapshot
2022Earnings Flash (CCXI) CHEMOCENTRYX Posts Q1 Revenue $5.46M
2022ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
2022ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
2022ChemoCentryx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
2022Chemocentryx, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
2022ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, ..
2022ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I T..
2022ChemoCentryx, Inc. Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Pha..
2022CHEMOCENTRYX, INC. Management's Discussion and Analysis of Financial Condition and Res..
2022Chemocentryx : Reports Fourth Quarter and Full Year 2021 Financial Results and Recent High..
2022ChemoCentryx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
2022Chemocentryx : Q4 Earnings Snapshot
2022Earnings Flash (CCXI) CHEMOCENTRYX Reports Q4 Revenue $2.3M, vs. Street Est of $3.9M
2022Earnings Flash (CCXI) CHEMOCENTRYX Reports Q4 Loss $-0.58, vs. Street Est of $-0.58
2022ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Hig..
2022Chemocentryx, Inc. : Change in Directors or Principal Officers (form 8-K)
2022ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Cal..
2022ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2022ChemoCentryx Announces EU Approval of TAVNEOS (avacopan) for the Treatment of ANCA-Asso..
2022ChemoCentryx Secures EU Approval for Vasculitis Treatment
2022ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Ass..
2022ChemoCentryx, Inc Announces EU Approval of Tavneos® for the Treatment of ANCA-Associate..
2022Vifor: feu vert européen pour Tavneos contre des vasculites
2022Chemocentryx : Corporate Presentation January 2022
2022ChemoCentryx to Present at Two Upcoming Investor Conferences
2021Insider Sell: Chemocentryx
2021ChemoCentryx, Inc. - Positive Recommendation for Use of TAVNEOS (avacopan) in ANCA Vasc..
2021Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted ..